Successful completion of first trial phase enables continued pivotal trial of FemBloc, the only non-surgical permanent birth control, toward U.S. FDA approval -- -- $12 million senior secured ...

What was once a niche benefit only offered by tech and financial service companies has expanded to industries of all sizes.

Globe reporter Jessica Bartlett discusses her special report on the in vitro fertilization industry, its shortcomings, and the growing role played by private equity.

While recent fertility drug-related announcements by the Trump administration could result in savings for women—especially ...

The White House Policy Council has missed its deadline by months to present a list of policy recommendations for protecting ...

IVF can run $12,000 to $25,000 per cycle, often with multiple rounds, and is not always fully covered by insurance ...

A lobbying blitz by social and religious conservatives paid off last week when Trump announced policies that fell short of his promise to make fertility treatments, which they oppose, free.

The FDA will move select drugs through the approval process in 1 to 2 months rather than the standard 10 months.

The Trump administration is turning to an unconventional approach to lowering drug prices in the United States: striking ...

There’s a difference between pro-birth and pro-life. Trump is undoubtedly hoping some of his supporters can’t tell the difference.

A new study has shown the ovary’s tissues and cells play a bigger role than previously thought in how fertility wanes.